▲ Plasmapp recently released a new product called 'ACTILINK motion' that applied implant plasma surface treatment technology at the SIDEX 2022 event.

Plasmapp (CEO Lim You-bong) recently released a new product called "ACTILINK motion" that applied implant plasma surface treatment technology at the SIDEX 2022 event. According to the company, Plasmapp was intensively promoted with Megagen Implant, a global implant manufacturer in Korea, and the new product was well received by many visitors.

At the SIDEX event, Plasmapp signed a contract with One Day Biotech (CEO Kim Jin-hwan), a fast-growing domestic implant manufacturer, and an MOU with Biotem Implant (CEO Lee Young-ho), a growing domestic implant manufacturer in Southeast Asia. In particular, in cooperation with One Day Biotech, it is increasing global competitiveness of implant products by applying packaging technology for plasma surface treatment, and licensing out for plasma patent technology was carried out together.

In addition, it has signed a supply contract with Dental OK (CEO Kim Kwang-jin), and plans to expand its technology to orthopedics, plastic surgery, and dermatology in terms of application markets by establishing various types of cooperation with the launch of new products. Including this contract, Plasmapp has recently secured about 140 billion won in accumulated contracts and has an order balance of more than 130 billion won.

In addition, at the SIDEX event, the CEO of the Clean Implant Foundation in Germany's guest lecture (Dr. Dirk Duddeck) on the importance of managing impurities on implant surfaces was held. In addition, a lecture on "Bio-Plasma Technology to Remove Impurities from Implant Surface" was successfully conducted at a technical seminar by Plasmapp CEO (Dr. Lim You-bong of Physics).

Meanwhile, Plasmapp discussed ways to cooperate with Clean Implants to create new technology standards in the global implant market, and decided to participate in the European Association of Osseointegration in Switzerland in September to introduce the importance of implant surface impurity management and bioplasma technology.